NEW YORK--(BUSINESS WIRE)--NOMADX Holdings LLC (“NOMADX Holdings”), a private company pioneering new technologies for biological and chemical detection, announced today that it has commenced operations to commercialize a portfolio of innovative products that will enable faster, more accurate portable testing in food, water, and air safety, as well as human healthcare, applications..

纽约--（商业新闻短讯）--NOMADX Holdings LLC（“NOMADX Holdings”）是一家开创生物和化学检测新技术的私营公司，今天宣布，它已经开始运营，将一系列创新产品商业化，这些产品将在食品、水和空气安全以及人类保健应用中实现更快，更准确的便携式检测。。

NOMADX Holdings, which is an acronym for Nano-Molecular Automated Diagnostics, was founded by Wilson Chatterji Ventures (“WCV”) and catalyzed through the asset purchase agreement of RamanID, Inc., founded by Ms. Reem Mahrat, earlier this year. The transaction was facilitated by law firm Foley & Lardner.

NOMADX Holdings是纳米分子自动诊断的缩写，由Wilson Chatterji Ventures（“WCV”）创立，并通过今年早些时候Reem Mahrat女士创立的RamanID，Inc.的资产购买协议进行催化。该交易由Foley&Lardner律师事务所促成。

WCV co-founder and life sciences and med-tech investor and expert, Anjan Chatterji, JD, MBA, LLM, will serve as Chief Executive Officer and Board Member of NOMADX. Chris Wilson, WCV partner and a 30-year senior partner of a multi-billion-dollar hedge fund, has been appointed Chairman of the NOMADX Board.

WCV联合创始人、生命科学和医学技术投资者兼专家Anjan Chatterji（法学博士、工商管理硕士、法学硕士）将担任NOMADX的首席执行官和董事会成员。WCV合伙人、一家数十亿美元对冲基金的30年资深合伙人克里斯·威尔逊（ChrisWilson）已被任命为NOMADX董事会主席。

Rounding out the NOMADX senior leadership team are a group of experienced industry executives who will operate from the company’s offices in New York City, New Delhi, India, and Boise, Idaho. They include:.

NOMADX高级领导团队由一群经验丰富的行业高管组成，他们将在该公司位于纽约市、印度新德里和爱达荷州博伊西的办事处工作。它们包括：。

Dakota Robinson (Chief Financial Officer): Mr. Robinson is a financial restructuring expert and U.S. Army veteran and West Point graduate with nearly a decade of relevant experience.

达科塔·罗宾逊（首席财务官）：罗宾逊先生是一位财务重组专家，美国陆军老兵，西点军校毕业生，拥有近十年的相关经验。

Jennifer Williams (Chief Operating Officer): Ms. Williams is a marketing and organizational expert with a long legacy in healthcare-focused hedge funds in New York.

詹妮弗·威廉姆斯（首席运营官）：威廉姆斯女士是一位营销和组织专家，在纽约专注于医疗保健的对冲基金领域拥有悠久的历史。

Lyle Probst, MBA (President, North America): Mr. Probst holds 20+ years of experience within operations and product development and engineering in the diagnostic and related biodefense industries.

Lyle Probst，MBA（北美总裁）：Probst先生在诊断和相关生物防御行业的运营、产品开发和工程方面拥有20多年的经验。

Rupesh Chaturvedi, Ph.D. (Scientific Advisor): Dr. Chaturvedi is a 20-year, tenured professor at India’s prestigious Jawaharlal Nehru University within its School of Biotechnology with experience in identifying and developing biomedical and life sciences solutions.

鲁佩什·查图尔维迪博士（科学顾问）：查图尔维迪博士是印度著名的贾瓦哈拉尔·尼赫鲁大学生物技术学院的20年终身教授，具有确定和开发生物医学和生命科学解决方案的经验。

Ishan Barman, Ph.D. (Scientific Advisor): Dr. Barman is a professor in the Department of Mechanical Engineering at Johns Hopkins University with 15+ years of experience within biomedical imaging, engineering, and entrepreneurialism.

伊珊·巴曼博士（科学顾问）：巴曼博士是约翰·霍普金斯大学机械工程系的教授，在生物医学成像、工程和创业方面拥有15年以上的经验。

At the core of the NOMADX cartridge-enhanced SERS (Surface-Enhanced Raman Scattering) platform is a patented surface coating that is applied to silicon chips using metallic nanoparticles. The novel technology significantly enhances the electromagnetic and chemical spectral scattering signal of molecules within a sample to create a multi-plex platform.

NOMADX墨盒增强SERS（表面增强拉曼散射）平台的核心是一种专利表面涂层，该涂层使用金属纳米粒子应用于硅片。这项新技术显着增强了样品中分子的电磁和化学光谱散射信号，从而创建了一个多重平台。

Internal validation studies have demonstrated that these enhancements allow the detection and quantification of a wide range of analytes at single-molecule detection levels. Further studies have shown that the NOMADX platform is as fast and simple to use as an ATP-based test, with results that can exceed the sensitivity, specificity, and speed (1-2-minute results) of traditional PCR testing..

内部验证研究表明，这些增强功能可以在单分子检测水平上检测和定量各种分析物。进一步的研究表明，NOMADX平台与基于ATP的测试一样快速简单，结果可以超过传统PCR测试的灵敏度，特异性和速度（1-2分钟结果）。。

'We are pleased to announce the launch of NOMADX Holdings, the natural selection in the evolution of food safety and human healthcare. The COVID pandemic saw a dramatic rise in the use of testing and created a positive perception of its value in the public. Despite the rapid introduction of tests during this time, it was also clear that very little innovation has taken place in portable, rapid testing over the last 20 years.

“我们很高兴宣布推出NOMADX Holdings，这是食品安全和人类医疗保健发展过程中的自然选择。新型冠状病毒大流行导致检测的使用急剧增加，并在公众中产生了对其价值的积极认识。尽管在此期间快速引入了测试，但很明显，在过去的20年中，便携式快速测试几乎没有创新。

We also saw the potential for contamination and the testing industry pushed past its limits. This led us to look at ways to disrupt this market and to the founding of NOMADX Holdings,” said Chatterji. “NOMADX aims to commercialize a new generation of powerful detection systems that will enable anyone to perform accurate, rapid, and cost-effective environmental and biological testing.

我们还看到了潜在的污染和测试行业超越其极限。查特吉说：“这促使我们寻找破坏这一市场的方法，并成立了NOMADX控股公司。”。“NOMADX的目标是将新一代功能强大的检测系统商业化，使任何人都能够进行准确、快速和经济高效的环境和生物检测。

This is not just a step forward, it's the true allowance of natural selection to advance the evolution of much needed preemptive and offensive technologies and applied applications that enable a safer, healthier future for us all.”.

这不仅仅是向前迈出的一步，它是自然选择的真正允许，可以推动急需的先发制人和攻击性技术以及应用程序的发展，从而为我们所有人创造更安全，更健康的未来。”。

The first commercial application of the NOMADX platform will enable on-site testing for the food safety and public water utilities industries. Foodborne illness, alone, is a preventable public health challenge and multi-billion-dollar burden. The World Health Organization (“WHO”) estimated in 2022 that 600 million – almost 1 in 10 people in the world – fall ill after eating contaminated food and 420,000 die every year, resulting in the loss of 33 million healthy life years.

NOMADX平台的首次商业应用将为食品安全和公共供水设施行业提供现场测试。单是食源性疾病，就构成了可预防的公共卫生挑战和数十亿美元的负担。世界卫生组织（WHO）估计，2022年有6亿人（世界上近十分之一的人）在食用受污染的食物后患病，每年有42万人死亡，导致3300万健康生命年的损失。

The WHO also estimates 1.7 billion people use a drinking water source contaminated with feces. Further, peer-reviewed studies have shown that approximately 80% of diseases and 50% of child deaths worldwide are related to poor water quality..

世卫组织还估计有17亿人使用受粪便污染的饮用水源。此外，同行评审的研究表明，全球约80%的疾病和50%的儿童死亡与水质差有关。。

The NOMADX platform utilizes label- and label-free testing, on a portable proprietary device, and can detect trace amounts of contaminants, including, but not limited to Salmonella, Listeria monocytogenes, Escherichia coli, PFAS, as well as clinical biomarkers, viruses, and other clinical applications using multi-plex technology on a single chip.

NOMADX平台在便携式专有设备上利用无标签和无标签测试，可以检测痕量污染物，包括但不限于沙门氏菌、单核细胞增生李斯特菌、大肠杆菌、PFA，以及临床生物标志物、病毒和其他在单芯片上使用多重技术的临床应用。

With a minute or less of sample prep, rapid testing can be done at a very low cost on food, its packaging, and preparation surfaces, and can also be used for the automated detection of contaminants in water, air, and in vitro. The cartridge and sample, after testing, can be retained for confirmatory testing, as the NOMADX protocol is non-destructive to the sample.

通过一分钟或更少的样品制备，可以以非常低的成本对食品，其包装和制备表面进行快速检测，也可以用于水，空气和体外污染物的自动检测。测试后，可以保留墨盒和样品进行确认测试，因为NOMADX协议对样品没有破坏性。

Further, spectral data are analyzed with the NOMADX data library and AI-based algorithm to produce results instantly for defined pathogen signatures, as well as those that have corollary signatures that have not yet been defined. The NOMADX platform pipeline will expand to include early detection in the field of oncology and rare diseases, as well as potential therapeutics for companion diagnostics..

此外，使用NOMADX数据库和基于AI的算法分析光谱数据，以立即产生定义的病原体特征以及尚未定义的推论特征的结果。NOMADX平台管道将扩展到包括肿瘤学和罕见疾病领域的早期检测，以及伴随诊断的潜在治疗方法。。

For more information about NOMADX platform and the company’s early access program, please visit: www.nomadxholdings.com.

有关NOMADX平台和公司早期访问计划的更多信息，请访问：www.nomadxholdings.com。

About NOMADX Holdings

关于NOMADX Holdings

NOMADX Holdings LLC, is pioneering new technologies for biological and chemical detection that include innovative products that will enable faster, more accurate testing in food, water, and air safety as well as human healthcare, applications. For more information about NOMADX and its mission to become the natural selection in the evolution of diagnostics, please visit www.nomadxholdings.com..

NOMADX Holdings LLC是生物和化学检测新技术的先驱，其中包括创新产品，这些产品将在食品、水和空气安全以及人类医疗保健应用中实现更快，更准确的检测。有关NOMADX及其在诊断学发展过程中成为自然选择的使命的更多信息，请访问www.nomadxholdings.com。。